|
||
| |||||||
|
|
SOLEXA TO PRESENT AT 24th ANNUAL JPMORGAN HEALTHCARE CONFERENCE HAYWARD, Calif. and Cambridge, UK (January 4, 2006) – Solexa, Inc. (Nasdaq: SLXA) today announced that John West, Chief Executive Officer of Solexa, will make a presentation to the investment community at the 24th Annual JPMorgan Healthcare Conference on Wednesday, January 11, 2006 at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco.
Interested investors may gain access to a live audio webcast and slide presentation via the Internet by visiting the “Investors – Conferences and Exhibitions” section of the Company’s Web site at www.solexa.com. The presentation will be archived on the web site and available for 14 days.
About Solexa Solexa, Inc. is developing and preparing to commercialize the Solexa Genome Analysis System, which will be used to perform a range of analyses including whole genome resequencing, gene expression analysis and small RNA analysis. Solexa expects its first-generation instrument, the 1G Genome Analyzer, to generate over a billion bases of DNA sequence per run and to enable whole genome resequencing below $100,000 per sample, making it the first platform to reach this important milestone. Solexa's longer-term goal is to reduce the cost of human re-sequencing to a few thousand dollars for use in a wide range of applications from basic research through clinical diagnostics. For further information, please visit www.solexa.com.
This press release contains "forward-looking" statements, including statements related to the current views of Solexa management as to future products, product development, commercialization of the Company’s novel genetic analysis technology, and the expansion and success of Solexa's commercial application of its genomics technologies. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "predicts," "expects," "envisions," "hopes," "estimates," "intends," "will," "continue," "may," "potential," "should," "confident," "could" and similar expressions are intended to identify forward-looking statements. There can be no assurance that such expectations of any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. There are a number of important factors that could cause the results of Solexa to differ materially from those indicated by these forward-looking statements including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2004 and its Form 10-Q for the quarter ended September 30, 2005. Solexa does not undertake any obligation to update forward-looking statements.
ENDS
For more information, please contact:
|
|
| ||||||||
